Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Strange Bedfellows: Regulators May Revive Biotech Deals And IPOs

Executive Summary

Still mourning the loss of IPOs and desperate for exits, biotechs could be forgiven for being pessimistic. But some experts say health reform and other new regulations will renew the value of innovative drugs and revive the crucial public markets

You may also be interested in...

Health Reform Magnifies Payers' Invisible Place At The Licensing Table

Report from Licensing Executives Society meeting: Survey shows many already have taken action oncomparative effectiveness.

Omeros Debuts With $68 Million IPO Despite Legal Hassles from Former CFO

Investors push the stock down on its first day, but the Seattle biotech now has cash to help get its late-stage pain compound to market.

FDA Continues "Tayloring" Senior Leadership

BIO executive VP John Taylor returns to the agency as special counselor while FDA also fills another key liaison slot.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts